Hikal Ltd Forensic Report - SOIC x StockScans Report

as of Sep 2026

Hikal's FY2025-26 record carries a regulator-reported fraud finding, a USFDA warning letter that crushed pharma margins, and a string of policy choices that flatter reported profits. The auditor filed two Form ADT-4 reports with the Central Government over employee document alteration, and separately flagged an environmental litigation stack of ₹25.8 crore with only ₹1 crore provisioned.

Key findings

  1. Employee document alteration forced an ₹80.7 crore revenue reversal Critical - Hikal disclosed on 26 Dec 2025 that certain employees altered documents relating to revenue recognition, and the company reversed ₹80.7 crore of Q2FY26 revenue. An external review found the irregularities were limited to preponement of genuine sales, with no impact on current or previous periods. The auditor filed two Form ADT-4 reports with the Central Government under section 143(12), and CARO explicitly excepted this as fraud.
  2. USFDA warning letter hit pharma sales and triggered a downgrade Major - The USFDA issued a Warning Letter on 21 August 2025 for the Jigani facility, citing inadequate investigations of customer complaints and shortcomings in vendor management. Pharma segment sales were impacted for the year ended 31 March 2026, and the segment's PBIT margin fell from 11.76% in FY25 to 3.21% in FY26. ICRA downgraded Hikal's long-term rating from ICRA A+ to ICRA A on 24 November 2025, citing the USFDA action and crop protection pressure.
  3. Hikal impaired ₹47.1 crore of its Panoli plant after deciding to repurpose it Major - Hikal recorded an impairment charge of ₹47.1 crore in FY2025-26 on assets no longer usable in a plant being repurposed. The plant had a written-down value of ₹248.9 crore as at 31 March 2026 and was not in commercial use. The Managing Director said the ₹300 crore agrochemical plant was "part impaired in Q4 last year and is now being retooled," but the impairment amount and retooling cost were not disclosed.
  4. Hikal carries ₹25.8 crore in disputed environmental compensation demands, with only ₹1 crore provisioned Major - The National Green Tribunal directed recovery of ₹17.5 crore from Hikal, which the Supreme Court stayed upon a ₹5 crore deposit, of which ₹1 crore was provisioned. The Karnataka Pollution Control Board served a demand notice for ₹8.3 crore, against which Hikal made no provision based on legal advice. The auditor has stated in each of the last four years that this matter "may have an adverse effect on the functioning of the Company".
  5. Seven clean opinions sit alongside a four-year audit-trail exception and a fraud finding Major - S R B C & CO LLP issued unqualified opinions for each year from FY2019-20 through FY2025-26. The auditor's proper-books opinion was qualified by an audit-trail exception in each of FY2022-23 through FY2025-26, stating the audit trail was not enabled for privileged users in one software. CARO states no cash losses were incurred, while the SQL snapshot shows PAT of -₹33.80 crore in the latest year and -₹48.80 crore in the immediately preceding year.
  6. Reported net-debt reduction coexists with factored receivables kept on-balance-sheet Major - Hikal transfers receivables to a factor for cash but retains credit risk and continues to recognise the transferred assets in their entirety, with the amount presented as borrowing. Margin money deposits of ₹4.4 crore are earmarked towards non-fund based bank facilities. The stated ideal gearing ratio is 35% to 40%, while net debt-to-equity was 0.59 in FY2024-25 and 0.67 in FY2023-24.
  7. Reported profits lean on policy choices and one-off items Major - Hikal depreciates ships over 30 years, "higher and different" from the 20-year life prescribed under Schedule II. The company capitalised exchange losses of ₹1.47 crore in FY2023 and ₹1.22 crore in FY2022 into fixed assets. Hikal booked a ₹38.0 crore exceptional charge for labour-code changes in FY2026, then reversed ₹9 crore of it as exceptional income in Q1 FY2027.
  8. Promoter family consolidates control while a director's continuation was rejected Major - Castilia Life Sciences LLP acquired 34.83% voting rights through a scheme of amalgamation and a subsequent conversion approved in February 2026. The special resolution for continuation of Mr. B. N. Kalyani as director beyond age 75 was NOT PASSED on 25 December 2023, and he resigned effective 29 December 2023. Remuneration paid to one managerial person for FY2023-24 exceeded statutory limits, with excess of ₹0.6 crore recognised as recoverable.

What to watch

Bottom line: This is a record with a regulator-reported fraud finding at its centre, surrounded by a USFDA enforcement action, a material environmental litigation stack, and profits that lean on policy choices. The clean audit opinions sit alongside a four-year audit-trail exception that the auditor finally called out as fraud. Watch the USFDA re-inspection timeline and the Supreme Court outcome, and read the reported leverage with the factored receivables in mind.